Details of the Drug Combination

General Information of Drug Combination (ID: DCRPXEI)

Drug Combination Name
Tenofovir disoproxil Telbivudine
Indication
Disease Entry Status REF
Chronic Hepatitis B Phase 4 [1]
Component Drugs Tenofovir disoproxil   DM62IPN Telbivudine   DMSWUGE
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Tenofovir disoproxil Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]
------------------------------------------------------------------------------------
Tenofovir disoproxil Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [4]
------------------------------------------------------------------------------------
Indication(s) of Telbivudine
Disease Entry ICD 11 Status REF
Hepatitis B virus infection 1E51.0 Approved [2]
Telbivudine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Hepatitis B virus Polymerase (HBV P) TTT4SY6 Q67889_HBV Inhibitor [5]
------------------------------------------------------------------------------------
Telbivudine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
NADH dehydrogenase 1 beta subcomplex subunit 8, mitochondrial (NDUFB8) OTW4A4Q0 NDUB8_HUMAN Decreases Expression [6]
Cytochrome c oxidase subunit 2 (COX2) OTTMVBJJ COX2_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hepatitis B, Chronic DCCGKED N. A. Phase 4 [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02774837) Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B
2 Nucleoside and nucleotide analogs in the treatment of chronic hepatitis B. Enferm Infecc Microbiol Clin. 2008 May;26 Suppl 7:32-8.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 FDA label of Bictegravir, emtricitabine, and tenofovir alafenamide. The 2020 official website of the U.S. Food and Drug Administration.
5 Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92.
6 Insights into the mechanisms of telbivudine-induced myopathy associated with mitochondrial dysfunction. Chem Biol Interact. 2023 Sep 25;383:110692. doi: 10.1016/j.cbi.2023.110692. Epub 2023 Sep 1.
7 ClinicalTrials.gov (NCT03468907) The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation